NCT05665530 2026-01-26
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
Clinical Trials
10 trialsNCT03583424 2025-05-14
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT03955783 2024-10-26
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT03357627 2023-02-08
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Calithera Biosciences, Inc
Phase 1 Completed
NCT03276468 2023-01-10
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT03082209 2022-12-09
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
Phase 1 Completed
NCT03036904 2022-08-24
V+DA-EPOCH-R
Weill Medical College of Cornell University
Phase 1 Completed
NCT02987400 2022-02-16
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT03255096 2022-01-24
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
Hoffmann-La Roche
Phase 1 Completed
NCT01742988 2021-05-06
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Curis, Inc.
Phase 1 Completed